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Abstract 
Growth hormone (GH) secreting pituitary adenomas are the main cause of acromegaly.  Somatostatin 
analogs are the gold standard of medical therapy; however, resistance represents a big drawback in 
acromegaly management. We recently demonstrated that benzene (BZ) modifies the aggressiveness of 
GH-secreting rat pituitary adenoma cells (GH3), increasing GH secretion and altering the synthesis of 
molecules involved in the somatostatin signaling pathway. Based on these pieces of evidence, this study 
aimed to evaluate the effects of BZ on octreotide (OCT) efficacy in GH-secreting adenoma cells. In GH3 
cells, BZ counteracted the anti-proliferative action of OCT. GH gene expression, unmodified by OCT, 
remained high in BZ-treated cells as well as after treatment with the association of both. GH secretion, 
reduced by OCT, was increased after treatment with BZ alone or when the pollutant was used with OCT. 
The combination of BZ and OCT greatly reduced the gene expression of ZAC1 and SSTR2; and this 
reduction was also present at a protein level. BZ caused an increase in the protein level of the 
transcription factor STAT3 and in its phosphorylated form. In the presence of BZ, OCT lost the ability 
to reduce the phosphorylated protein levels. Finally, in primary cultures of human pituitary adenoma 
cells, BZ caused an increase in GH secretion. OCT decreased GH secretion, but the addition of BZ 
reversed the OCT effect. In conclusion, our results suggest that BZ may have an important role in the 
resistance of pituitary adenomas to the pharmacological treatment with somatostatin analogs. 
 
Keywords: pollution; benzene; GH; octreotide; pituitary adenoma. 
 
Abbreviations: Abbreviations: AHR = aryl hydrocarbon receptor; AIP = aryl hydrocarbon receptor-
interacting protein; BZ = benzene; DEHP = bis(2-ethylhexyl) phthalate; GH = growth hormone; GH3 = 
GH-secreting rat pituitary adenoma cells; MAPK = mitogen-activated protein kinase; OCT = octreotide; 
PTP = phosphotyrosine phosphatase; SS = somatostatin; SSA = somatostatin analogs; SSTR = 
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somatostatin receptor; STAT3 Signal transducer and activator of transcription 3; ZAC1 = zinc-finger 
protein. 
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Introduction 
Growth hormone (GH) secreting pituitary adenomas (10-12 % of pituitary secreting tumors) are the main 
cause of acromegaly, a rare but severe and complex endocrine disease resulting from increased 
circulating GH levels (Melmed 2015, Mehta & Lonser 2017). 
The available therapeutic approaches for acromegaly consist in neurosurgery, radiotherapy and medical 
therapy whose gold standard is the treatment with somatostatin analogs (SSAs) (Melmed et al. 2018, 
Cuevas Ramos & Fleseriu, 2014, Paragliola et al. 2017). SSAs mimic the physiological somatostatin 
actions; they actually bind to somatostatin receptors (SSTRs) and induce a conformational change of 
SSTRs that leads to activation of an associated heterodimeric G-protein complex, that through the 
induction of various intracellular cascades, finally results in antiproliferative and antisecretory effects. 
Pathways and effects on cellular function may be different according to each specific SSTR subtype. 
Five different subtypes of SSTRs have been identified (SSTR1-5), each one being encoded by genes 
situated on different chromosomes (Patel 1999). Octreotide (OCT), the first SSA used in clinical 
practice, still widely used for acromegaly treatment, is an octapeptide with high binding affinity for 
SSTR2 and, to a lesser extent, for SSTR5. In general, SSTRs signaling inhibits adenyl cyclase activity 
and modulates potassium and calcium channels involved in hormone secretion; it affects 
phosphotyrosine phosphatase (PTP) and/or mitogen-activated protein kinase (MAPK) activity, involved 
in cell growth and differentiation. Moreover, PTP has been described to modulate the 
phosphorylation/activity of the signal transducer and activator of transcription 3 (STAT3) that is 
implicated in both GH synthesis as well as in cell growth, survival and differentiation. 
Zinc-finger protein (ZAC1) is a transcription factor and coregulator that plays a key role in the signal 
transduction following SSTR2 activation (Theodoropoulou et al. 2010). It is involved in the development 
of normal pituitary and in tumorigenesis process; many studies have shown that its function is essential 
for SSA efficacy (Theodoropoulou et al. 2009, Chahal et al. 2012). 
Unfortunately, some GH-secreting adenomas are resistant to octreotide therapy. Resistance to SSA, 
consisting in lack of hormonal normalization, increase in tumor size or tumor shrinkage less than 20% 
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compared with baseline tumor (Paragliola et al. 2017) and represents a big drawback in acromegaly 
management. 
The molecular basis of different sensitivity of GH pituitary tumors to SSA has been widely investigated 
over the last years. The density of SSTRs with high affinity for SSA, mutations of genes encoding for 
SSTRs, desensitization of SSTRs for the uncoupling to the signaling cascade (Colao et al. 2011) have 
been identified as main factors underlying this phenomenon. Nevertheless, other elements may interfere 
with pharmacological response, such as other genetic mutations as well as epigenetic and environmental 
factors (Zhou et al. 2014, Dzobo et al. 2018). 
Nowadays, pollution is a critical issue because of its adverse effects on human health. Benzene (BZ) is 
a very common environmental pollutant; its main sources are vehicle exhaust fuels, evaporation during 
handling and storage of petrol, industrial emissions and cigarette smoking.  
Recent epidemiologic studies suggest an involvement of environmental pollution in pituitary adenoma 
outbreaks. As a consequence of Seveso accident in 1976 Pesatori and colleagues (2008) observed an 
increasing trend in pituitary adenomas incidence in areas characterized by high dioxin contamination. In 
the highly polluted area close to Messina (Italy) Cannavò et al. (2010) encountered a significantly higher 
prevalence of acromegaly respect to less polluted areas and to the general population. Patients living in 
highly polluted areas and carriers of genetic variants affecting normal functioning of the aryl hydrocarbon 
receptor (AHR) pathway (that is involved in xenobiotics cellular response) present larger pituitary 
tumors, more severe acromegaly symptoms, and are more frequently SSA resistance (Cannavò et al. 
2016). 
A link between epidemiological and molecular studies is provided by the in vitro study of Tapella et al. 
(2016) showing that pollutants such as BZ and DEHP (di-2-ethylhexyl phthalate) can modify normal rat 
pituitary cell proliferation and induce gene expression changes of AHR and other related genes.  
Furthermore, our recent study (Fortunati et al. 2017) demonstrated that some common chemical 
pollutants are able to induce modifications in molecules related to GH secretion and somatostatin 
signaling pathway, focusing on their capacity of enhancing aggressiveness and modifying biological 
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behavior of pituitary tumors. Effects observed on ZAC1 and SSTR2 may imply an important role in 
sensitivity of pituitary adenomas to medical treatment. Based on these evidences, this study aimed to 
evaluate the effects of BZ on OCT efficacy in GH secreting adenoma cells, by investigating cell 
proliferation, GH expression and secretion, gene expression and protein level of molecules involved in 
somatostatin signaling pathway as well as phosphorylation status of STAT3.   
 7 
 
Materials and Methods  
Chemicals 
Benzene (BZ) was purchased from Sigma-Aldrich Co. (St. Louis, MO) and was dissolved in DMEM-
F12 medium added with dextran-charcoal stripped sera (12.8 M). The experimental dose (130 pM) was 
within ranges observed in blood of exposed people (Hines at al. 2009, Yan et al. 2009, Hays et al. 2012, 
Chovancova et al. 2012) and as previously assessed in our recent study (Fortunati et al. 2017). Octreotide 
(OCT) was kindly provided by Novartis Pharma AG (Basel, Switzerland). Experimental doses (10 nM, 
100 nM, and 1 M) were within ranges in blood of treated patients as shown in pharmacokinetics studies 
(Tuvia et al. 2012). 
Cell cultures 
Rat pituitary adenoma GH3 cells, obtained from the American Type Culture Collection (ATCC), were 
maintained in DMEM-F12 culture medium (Lonza, Switzerland) supplemented with 2.5% fetal calf 
serum and 15% horse serum (Gibco, UK), at 37° C in a humidified atmosphere of 95% O2 and 5% CO2. 
Antibiotics (100 UI/ml penicillin and 100 g/ml streptomycin) were added to growth media. The cells 
were routinely screened for mycoplasma contamination, and kept in serum-free medium for the 24 hours 
preceding the treatments with BZ and/or OCT.  
Cell viability assay 
Cell viability was assessed using Cell Proliferation Reagent WST-1, a colorimetric assay based on the 
cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases in viable cells (Roche Applied 
Science, Penzberg, Germany). The cells were seeded in 96-well plates at a density of 1 x 104 cells/well. 
After 72 hours the cells were treated with 10 nM - 1 M OCT in the presence or absence of 130 pM BZ; 
untreated cells were used as control. At different time points (i.e. 0, 24, 48 and 72 hours) 10 l of WST-
1 was added to each well and after 1 hour incubation, absorbance at 450 nm was measured using a plate 
reader (Model 680 Microplate Reader, Bio-Rad, Hercules, CA, USA). Four replicate wells were used to 
determine each data point. 
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Gene expression profile 
Real Time PCR was used to evaluate the expression of GH, SSTR2, ZAC1, aryl hydrocarbon receptor 
interacting protein (AIP), and aryl hydrocarbon receptor (AHR). To assess gene expression profile, GH3 
cells were seeded in cell culture flasks (25 cm2) at a density of 1 x 106 cells/flask, and then treated for 
72h with 10-100 nM OCT in the presence or absence of 130 pM BZ. 
Total RNA was extracted using TRIzol Reagent (Invitrogen Ltd, Paisley, UK), and 1 µg of the total 
RNA reverse-transcribed with iScript cDNA Synthesis Kit (BioRad Laboratories, Inc.), following 
manufacturer’s protocol. Specific primers were designed using Beacon Designer 5.0 software; primers 
sequences are shown in Table 1. 
Real-time PCR was performed using a BioRad MiIQ Detection System (BioRad Laboratories, Inc.) with 
SYBR green fluorophore. Reactions were performed in 15 μl volume, which included 7.5 μl IQ SYBR 
Green Supermix (BioRad Laboratories, Inc.), 0.3 µl each primer at 10 μM concentration, 1.90 μl RNAse-
free distilled water, and 20 ng/5 µl of the previously reverse-transcribed cDNA template. For each primer 
set, the reaction was optimized using seven serial 5X dilutions of template cDNA obtained from cells in 
basal conditions (100, 20, 4, 0.8 and 0.16 ng). A melting curve analysis was performed following each 
run to ensure a single amplified product for each reaction. All reactions were carried out at least three 
times for each sample. Every gene expression level was normalized on the expression of three house-
keeping genes (β-Actin, L13A and β-2-microglobulin) and expressed as relative expression fold vs 
untreated controls.  
Western blot 
GH3 cells were seeded in cell culture flasks (25 cm2) at a density of 1 x 106 cells/flask, and treated with 
10-100 nM OCT in the presence or absence of 130 pM BZ.  At different times after treatment, the cells 
were scraped from the flask in the presence of 1 ml lysis buffer (50 mM Tris–HCl pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% sodium deoxycholate, 1% Nonidet P-40, 0.1% SDS, 10 mg/ml 
PMSF, 30 µl/ml aprotinin and 100 mM sodium orthovanadate). Cell lysates were incubated in ice for 30 
min. At completion, tubes were centrifuged at 4 °C for 20 min at 15,000 × g. Clear supernatants were 
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stored at −80 °C until use. Proteins were separated on 10% SDS-PAGE for ZAC1 and SSTR2, 
transferred to PVDF and probed with the following antibodies: polyclonal anti-ZAC1 (1:1000, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), polyclonal anti-SSTR2 (1:500 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA). 
For the evaluation of STAT3 and its phosphorylated form pSTAT3, a monoclonal anti-PAN-STAT3 
(1:1000, Cell Signaling Technology, Leiden, The Netherlands) and a polyclonal anti-Phospho-STAT3 
(Tyr705) antibody (1:500, Cell Signaling Technology, Leiden The Netherlands) were used. 
The membranes were then stripped and re-probed with a rabbit polyclonal anti-GAPDH antibody 
(1:10000, Sigma, Saint Louis, MO, USA) to check protein loading. Proteins were detected with Pierce 
Super Signal chemiluminescent substrate. The bands were photographed and analyzed using Kodak 1D 
Image Analysis software. 
Growth hormone secretion 
GH3 cells were seeded in cell culture flasks (25 cm2) at a density of 1 x 106 cells/flask, and treated with 
10-100 nM OCT in the presence or absence of 130 pM BZ.  After a 72h exposure, cell medium was 
centrifuged and collected; secreted GH was measured in the medium using the Rat Growth Hormone 
ELISA Assay (KRC5311, Invitrogen Ltd, Paisley, UK), following manufacturer’s instructions. 
Primary culture establishment and GH-secretion 
Pituitary adenoma samples were collected from patients that underwent surgery at the Division of 
Neurosurgery of Città della Salute e della Scienza University Hospital (Turin, Italy). Informed consent 
to the study was obtained from each patient, and the use of tissue samples was approved by “The 
Commitment for Human Specimen Utilization” of the Department of Medical Sciences, University of 
Turin. The study was carried out in accordance with The Code of Ethics of the World Medical 
Association (Declaration of Helsinki). 
Tissue samples were obtained by transsphenoidal surgery from 8 patients with GH-secreting pituitary 
adenomas. The diagnosis was established on the basis of clinical and biochemical characteristics of the 
patients and afterwards it was confirmed by the pathologist on the basis of both histology and 
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immunohistochemistry of the tumor sample. The tissues were collected under sterile conditions and 
processed immediately. Samples were washed three times in saline added with penicillin/streptomycin 
and nystatin. 
Enzymatic digestion was performed using 0.35% collagenase (Sigma, Milano, Italy) at 37°C for 60 min. 
Cell suspensions were filtered through double layers of sterile gauze and washed twice with D-MEM-
F12 plus 10% FCS. The cells were resuspended in complete medium added with 100 IU/ml penicillin 
and 100 g/ml streptomycin, 50g/ml gentamicin, 2.5g/ml amphotericin B, 15% HS and 2.5% FCS. 
Cells were plated at 2 X 105 cells/well depending upon the abundance of the tumor specimen and after 
72 hours treated with 100 nM OCT in the presence or absence of 130 pM BZ. Untreated cells were used 
as control. After 72 hours of treatment cell media were centrifuge and collected; GH secretion was 
evaluated using GH IRMA (IM1397, Beckman Coulter Inc., Chaska MN USA). 
Statistical analysis 
Data are expressed as mean ± SD, calculated on at least three independent experiments (N=3). The 
comparison between different treatments and control groups was performed with one-way ANOVA and 
the threshold of significance was calculated with the Bonferroni test. To analyze the effects of 
combination of BZ and OCT, the comparison between groups was performed with analysis of two-way 
ANOVA, and the threshold of significance was calculated with the Bonferroni test. Statistical 
significance was set at p<0.05.   
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Results 
GH3 cells viability 
OCT significantly reduced GH3 cells viability compared to control at 48 and 72 hours, but combined 
treatment with BZ abolished this effect. In particular, 48 hour treatment with 10 nM OCT decreased cell 
viability of 32.2%, while addition of BZ partially abolished OCT effect (18.7% reduction vs control) 
(Fig. 1A). 100 nM OCT reduced cell viability of 31% at 48 hours, and of 42.4% at 72 hours, addition of 
BZ to 100 nM OCT restored cell viability to control values at 48 hours and significantly reduced the 
antiproliferative OCT action of 20% at 72 hours (Fig. 1B). 1 µM OCT reduced cell viability of 26.8% 
at 48 hours and of 49.5% at 72 hours; treatment with BZ (Fig. 1C) decreased efficacy of 1 µM OCT 
treatment alone at 72 hours (reduction of 24.8% for 1 µM OCT plus BZ). BZ alone had no significant 
effect on cell viability. 
GH gene expression and secretion 
 
After 72 hour exposure, BZ induced GH gene expression (2.8 fold). An increased expression was also 
maintained when BZ was added to 10 and 100 nM OCT (1.6 fold vs OCT for both doses; 1.7 fold and 
1.8 fold vs control respectively) (Fig.2A). As far as GH secretion is concerned, it was significantly 
reduced by 10 and 100 nM OCT (46.4%, and 24%, respectively) (Fig.2B) and significantly increased by 
BZ of 29.3%. A higher GH secretion (15% vs control and 114% vs 10 nM OCT), was also maintained 
with 10 nM OCT and BZ. 
Somatostatin pathway: SSTR2, ZAC1 expression and production 
Fig. 3A shows a reduction of ZAC1 gene expression by the combined treatment of both 10 and 100 nM 
OCT with BZ (vs OCT alone: 0.23 fold, and 0.24 fold, respectively; vs control: 0.20 fold, and 0.26 fold, 
respectively). BZ alone, as expected (Fortunati et al., 2017), did not modify ZAC1 gene expression. At 
protein level, western blot (Fig. 3B e 3C) revealed a reduction of ZAC1 after BZ exposure (0.7 fold), 
also present when cells were treated with 100 nM OCT plus BZ compared to 100 nM OCT alone (0.61 
fold) and to control (0.56 fold). SSTR2 gene expression was highly decreased when BZ was added to 
OCT at both used concentrations in comparison with respective doses of drug alone (0.00015 fold for 
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10 nM OCT plus BZ, and 0.00048 fold for 100 nM OCT plus BZ; 0.38 fold for 10 nM OCT plus BZ vs 
control) (Fig. 3D). BZ reduced SSTR2 protein (0.8 fold) and significant effects were observed with 
combination of OCT and BZ in comparison with respective doses of OCT alone (0.72 fold 10 nM OCT 
plus BZ versus 10 nM OCT and 0.47 fold vs control; 0.25 fold 100 nM OCT versus 100 nM OCT, and 
0.16 fold vs control). A reduction of SSTR2 protein was observed even when cells were treated with 10 
e 100 nM OCT alone (0.64 fold, and 0.62 fold, respectively) (Fig. 3E and 3F). Gene expression of AIP 
and AhR were almost unmodified except for a slight reduction induced by 10 nM OCT plus BZ on AhR 
gene expression (p< 0.05) (Fig. 4). 
STAT3 phosphorylation  
Western blot (Fig. 5A) demonstrated that OCT statistically reduced STAT3 phosphorylation (Phospho-
STAT3) at 10 nM (Fig. 5A and 5B) (0.8 fold) and at 100 nM (Fig. 5B) (0.18 fold).  BZ increased 
Phospho-STAT3 (1.6 fold) and the addition of BZ to 10 or 100 nM OCT resulted in higher levels of 
Phospho-STAT3 compared to treatment with the drug alone (10 nM OCT plus BZ 5.25 fold, and 1.38 
fold vs control; 100 nM OCT plus BZ 4.9 fold vs 100 nM OCT). BZ enhanced Pan-STAT3 protein (1.8 
fold) (Fig. 5C), while 100 nM OCT reduced Pan-STAT3 (0.70 fold) as did 100 nM OCT plus BZ (0.71 
fold). 
GH secretion in primary culture cell medium 
Fig.6 shows that BZ caused an increase in GH secretion of pituitary adenoma primary culture cells 
(38%). 100 nM OCT decreased GH secretion of 26.5 %, while addition of BZ reversed this effect and 
GH secretion resulted significantly higher compared to cells treated with 100 nM OCT alone (56%).  
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Discussion 
For the last years, the interest on the effects of pollution on human health has been increasing and many 
studies demonstrated the relationship between pollutant exposure and the onset of several diseases. 
Many substances have been linked to endocrine tumor occurrence, but so far no study investigated the 
influence of pollution on the effectiveness of the pharmacological treatment of these diseases. 
Based on our recent study (Fortunati et al. 2017), showing the ability of some common pollutants to 
modify the behavior of pituitary adenoma cells and the expression of molecules involved in the 
somatostatin signaling, this study aimed to evaluate the influence of benzene (BZ) on the somatostatin 
analogue octreotide (OCT) in the treatment of GH-secreting pituitary adenomas. 
First, BZ reduced the efficacy of OCT in inhibiting GH3 cell proliferation. In this cell line model, BZ 
used alone had no effect on cell viability (Fortunati et al. 2017), but other studies conducted in normal 
rat pituitary primary cells showed an increased cell viability and proliferation induced by this chemical 
(Tapella et al. 2016), indicating that the effects can depend on cell type.  
GH gene expression was not modified by OCT alone; exposure to BZ increased GH mRNA levels and 
this effect persisted also in cells treated with BZ and OCT. Even though data about the action of 
somatostatin on GH gene expression are not conclusive, it was suggested that somatostatin mainly acts 
on GH protein remodeling and secretion, lowering circulating GH levels, without inducing mRNA 
modifications (Eigler & Ben-Shlomo 2014). 
Accordingly, our results revealed that OCT was very effective in lowering GH secretion in the medium; 
BZ was able to counteract this effect when the cells were treated with the lowest dose of OCT (10 nM). 
Also in human primary cultures OCT and BZ showed the same behavior. OCT significantly reduced GH 
secretion but the presence of BZ abolished this action. 
SSTR2 and ZAC1 are important molecules involved in the somatostatin signaling. SSTR2 expression at 
cell membrane is essential for OCT action since SSTR2 is the receptor with the highest affinity for this 
drug. Low expression of SSTR2 results in a poor response to SSA treatment (Taboada et al. 2008, Ferone 
et al. 2008). BZ lowered SSTR2 protein level and the effect was very strong even in the presence of 
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OCT. A reduction of SSTR2 protein was evident also when the cells were treated with OCT alone. As a 
consequence of OCT binding SSTR2 reduction is likely to be due to receptor internalization. This 
phenomenon could account for the increased SSTR2 mRNA levels after OCT treatment, but reduced 
SSTR2 protein in cells treated with the combination of OCT and BZ. 
ZAC1 controls cell proliferation and hormone synthesis and it is highly expressed in all hormone-
producing cells of the pituitary. It exerts a pivotal role in SSA effects in pituitary cells (Theodoropoulou 
et al. 2009), and its loss of expression is frequently detected in pituitary adenomas (Theodoropoulou et 
al. 2010).  
In our study, ZAC1 gene expression was not modified either by BZ or by OCT treatment, but it was 
reduced by the association of both compounds. At protein level, BZ induced a reduction of ZAC1 and 
this effect was present even when cells were treated with OCT at the same time. These results suggest 
that BZ may significantly impair this fundamental signaling pathway for OCT function. 
Other studies reported an increase in ZAC1 gene expression after OCT exposure; nevertheless, they are 
hardly comparable to our data, because of the different experimental conditions (very short time of 
treatment and different drug concentration) (Theodoropoulou et al. 2006).  
Some studies found a link between AIP and ZAC1 levels and suggested that this signaling pathway is 
important for SSA effects (Chahal et al. 2012). Actually, we could not observe any modification in AIP 
expression as well.  
STAT3 is an important transcription factor and its dysregulated activation has been encountered in many 
types of cancers (Buettner et al. 2002, Bromberg et al. 2002). It is involved in cell survival and 
proliferation and in the pituitary it is also associated with GH synthesis (Zhou et al. 2016). Constitutively 
STAT3 activation has been also implicated in chemo-resistance (Real et al. 2002, Bharti et al. 2004, 
Boehm et al. 2008) and radio-resistance (Otero et al. 2006). 
In our study we reported that OCT was able to reduce STAT3 phosphorylation accordingly to studies 
conducted in different types of tissues, as in retina explants (Mei et al. 2012). It was also reported that 
in GH4 pituitary adenoma cells OCT determined a reduction of STAT3 phosphorylation coupled with a 
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reduction in GH protein levels (Ezzat et al. 2017). This effect was mediated through activation of PTPs 
(e.g. SHP-1 or SHP-2) and it could be one of the pathways induced by OCT. 
Exposure of cells to BZ, instead, increased STAT3 phosphorylation and counteracted OCT action. 
Diesel exhaust particles (Cao et al. 2007), tobacco smoke (Nagpal et al. 2002) and other carcinogens 
have been reported to activate STAT3., Other studies linked BZ to STAT3 gene expression as a 
consequence of epigenetic modifications (Yang et al. 2014) and alteration of its phosphorylation status 
was seen in plasma of BZ exposed people (Fenga et al. 2016). Therefore, STAT3 activation may have a 
key role in BZ pathogenic mechanism as well as in OCT response. It  therefore deserves to be studied 
in detail. 
Our results showed that BZ can interfere with pituitary adenoma response to SSA. Actually BZ reduced 
the action of octreotide on GH3 cells at many levels. BZ counteracted OCT capacity to inhibit cell 
proliferation and to reduce GH secretion. BZ modified molecular pathways involved in OCT mechanism 
of action; ZAC1 and SSTR2 gene expression and protein levels as well as the amount and 
phosphorylation status of STAT3 protein were affected by BZ exposure even in presence of OCT. 
Taking together these results indicate that BZ is an environmental factor that could play an important 
role in pituitary adenoma responsiveness to SSA therapy. At present, only indirect evidence of the role 
of benzene exposure in SSA resistance in humans with GH-producing adenomas are available (Cannavò 
et al. 2016).  Indeed, in 2016 Cannavò et al. observed more frequent SSA resistance in acromegalic 
patients living in highly polluted areas and carriers of AHR genetic variants. Therefore, our study can 
represent the rationale for investigating benzene levels and SSA responsiveness in humans treated with 
octreotide for GH-secreting adenomas. Overall, a better understanding of the role of BZ as well of other 
environmental pollutants in the resistance to pharmacological treatments will be achieved. 
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Figure legends 
Figure 1 - Effects of OCT, BZ and OCT + BZ on GH3 cells proliferation. Cell viability after 
treatments with 10 nM (A) 100 nM (B) and 1 uM OCT (C), 130 pM BZ and their association for 
24,48 and 72 h. Data are expressed as viability ratio vs T0 of three independent experiments (N=3). 
Significance vs Control: * p<0.05; ** p<0.01; *** p<0.001. Significance vs OCT treatment: # p<0.05;  
## p<0.01; ### p<0.001. 
 
Figure 2 - Effects of OCT, BZ and OCT + BZ on GH in GH3 cells. mRNA expression of GH after 
treatments with 10 and 100 nM OCT, 130 pM BZ and their association for 72 h (A). Results are 
normalized for three different housekeeping genes (β-actin, β2μ and L13A) and are expressed as 
relative expression fold vs. control (N = 3).  GH (ng/ml) secreted by GH3 cells after OCT, BZ and 
OCT + BZ exposure for 72 h (B) (N=3). Significance vs Control: * p<0.05; ** p<0.01; *** p<0.001. 
Significance vs OCT treatment: ° p<0.05; °° p<0.01; °°° p<0.001. 
 
Figure 3 - Effects of OCT, BZ and OCT + BZ on ZAC1 and SSTR2. mRNA expression of ZAC1 
(A) and SSTR2 (D) after treatments with 10 and 100 nM OCT, 130 pM BZ and their association 72 
h. Results are normalized for three different housekeeping genes (β-actin, β2μ and L13A) and are 
expressed as relative expression fold vs. control (N = 3). Western blot for ZAC1 (B) and SSTR2 (E), 
anti-GAPDH was used to confirm equal loading; the images show a typical experiment. 
Semiquantitative analysis of western blot results for ZAC1 (C) and SSTR2 (F) of three independent 
experiments (N=3). Significance vs Control: * p<0.05; ** p<0.01; *** p<0.001.  Significance vs OCT 
treatment: ° p<0.05; °° p<0.01; °°° p<0.001. 
 
Figure 4 - Effects of OCT, BZ and OCT + BZ on AIP and AhR. mRNA expression of AIP and 
AhR  after treatments with 10 and 100 nM OCT, 130 pM BZ and their association 72 h. Results are 
normalized for three different housekeeping genes (β-actin, β2μ and L13A) and are expressed as 
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relative expression fold vs. control (N = 3): * p<0.05; ** p<0.01; *** p<0.001.  Significance vs OCT 
treatment: ° p<0.05; °° p<0.01; °°° p<0.001. 
 
Figure 5 - Effects of OCT, BZ and OCT + BZ on Phosphorylated STAT3 protein (Phospho-
STAT3) and Total STAT3 protein (Pan-STAT3). Western blot for and Pan-STAT3 (A), anti-
GAPDH was used to confirm equal loading; the image shows a typical experiment. Semiquantitative 
analysis of western blot results for Phospho-STAT3 (B) and Pan-STAT3 (C) of three independent 
experiments (N=3). Significance vs Control: * p<0.05; ** p<0.01; *** p<0.001.  Significance vs OCT 
treatment: ° p<0.05; °° p<0.01; °°° p<0.001. 
 
Figure 6 - Effects of OCT, BZ and OCT + BZ on GH in pituitary adenoma primary cell cultures. 
GH (ng/ml) secreted by cells after OCT, BZ and OCT + BZ exposure for 72 h. Significance vs 
Control: * p<0.05; ** p<0.01; *** p<0.001. Significance vs OCT treatment: ° p<0.05; °° p<0.01; °°° 
p<0.001. 
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Table 1- Primers for real time PCR 
Primers Sequences (5’-3’) 
GH 
sense TCGCTTCTCGCTGCTGCTC 
antisense TGCTTGAGGATCTGCCCAATACG 
SSTR2 
sense TACTTCGTGGTGTGCGTGGTG 
antisense CTTGGCGTAGCGGAGGATGAC 
ZAC1 
sense GGCAAGAGGAGCGGAGAGC 
antisense AATCAAGCAGGAACAACCACACG 
AIP 
sense TCGTGCGTACCATGCGTGAG 
antisense TGTTGCGGAGGCTCTTGGC 
AhR 
sense ACCAGTGTAGAGCACAAGTCAGAG 
antisense AGACGCATAGAAGACCAAGGCATC 
-actin 
sense CCACACCCGCCACCAGTTC 
antisense GACCCATACCCACCATCACACC 
microglobulin 
sense TCTTTCTGGTGCTTGTCTCTCTGG 
antisense CTATCTGAGGTGGGTGGAACTGAG 
L13A 
sense AGGTGGTGGTTGTACGCTGTG 
antisense GGTTGGTGTTCATCCGCTTTCG 
 
 
 
  
